A microdialysis study of the novel antiepileptic drug levetiracetam: Extracellular pharmacokinetics and effect on taurine in rat brain

British Journal of Pharmacology

Volumn 133, Issue 6, 2001, Pages 867-874

  Tong, X ^a   Patsalos, P N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amino acids; Extracellular fluid; Frontal cortex; Hippocampus; Levetiracetam; Microdialysis; New antiepileptic drug; Pharmacokinetics

Indexed keywords

AMINO ACID; ANTICONVULSIVE AGENT; ETIRACETAM; TAURINE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TRANSPORT; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034892646     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704141     Document Type: Article

References (62)

1. Characterisation of hippocampal norepinephrine release as measured by microdialysis perfusion: Pharmacological and behavioural studies
2. Attenuation by chlormethiozole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat
3. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: A multicentre, double-blind, responder-selected study evaluating monotherapy
4. Brain microdialysis
5. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
6. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum
7. Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission
8. Correlation between amino acids release and neuropathological outcome in rat brain following middle cerebral artery occlusion
9. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial
10. Kinetics of drug action in disease states. 1. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex
11. Dialytrode technology and local profiles of amino acids in the awake rat brain
12. Pharmacokinetic modelling of the anticonvulsant action of phenobarbital in rats
13. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat
14. Levetiracetam in a chronic model of epilepsy
15. Serum, cerebrospinal fluid, and brain concentrations of a new zidovudine formulation following chronic administration via an implantable pump in dogs
16. Automated amino acid analysis using combined FMOC-CL precolumn derivatization
17. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
18. Levetiracetam (ucb LO59): Anticonvulsant effects are mediated by the parent compound
19. ucb L059, a novel anti-convulsant drug: Pharmacological profile in animals
20. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy
21. Venlafaxine: Acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo
22. Concurrent determination of effects of p-chloramphetamine on central extracellular 5-hydroxytraptamine concentration and behaviour
23. Tiagabine antinociception in rodents depends on GABA(B) receptor activation: Parallel antinociception testing and medial thalamus GABA microdialysis
24. Photo-sensitive epilepsy: A model to study the effect of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
25. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
26. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats
27. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats
28. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata
29. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy
30. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo
31. A receptor-associated epileptiform effect of bicuculline in rat hippocampus
32. New drug treatments for epilepsy
33. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes
34. An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and halothane anaesthetised rats
35. The new generation of anti-epileptic drugs
36. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
37. The use of microdialysis for the study of drug kinetics: Some methodological consideration illustrated with antipyrine in rat frontal cortex
38. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): Hematological and biochemical characterization and kinetic evaluation using carbamazepine
39. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography
40. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus acumbens of freely-moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers
41. Gabapentin modifies extracellular opioid peptide content in amygdala: A microdialysis study
42. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: An in vivo microdialysis study in freely moving rats
43. Decreased GABA release following toni-clonic seizures is associated with an increase in extracellular glutamate in rat hippocampus in vivo
44. Incidence and prevalence studies in epilepsy and their methodological problems: A review
45. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy
46. Multicentre double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory seizures
47. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain
48. Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid
49. Microdialysis in pharmacokinetics
50. Drug distribution studies with microdialysis. II. Caffeine and theophyl-line in blood, brain and other tissues in rats
51. Pharmacokinetic studies of aspirin in rats using in vivo microdialysis sampling
52. Examination of microdialysis sampling in a well-characterized hydrodynamic system
53. Investigation into the role of N-acetylaspartate in cerebral osmoregulation
54. Extracellular fluid (ECF) kinetics of vigabatrin (VGT) in rat frontal cortex and hippocampus
55. Brain cortical amino acids measured by intracerebral dialysis in portocaval shunted rats
56. Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex
57. Comparison of single- and repeated-dose pharmacokinetics of diazepam
58. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine
59. The simultaneous estimation of the influx and efflux blood- brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach
60. Scope and limitations of in vivo brain dialysis: A comparison of its application to various neurotransmitter systems
61. Characterisation of in vivo dopamine release as determined by brain microdialysis after acute and subchronic implantation: Methodological aspects